BR0116482A - Derivados de difenilazetidinona, processo para a preparação, medicamentos contendo esses compostos e seu emprego. - Google Patents

Derivados de difenilazetidinona, processo para a preparação, medicamentos contendo esses compostos e seu emprego.

Info

Publication number
BR0116482A
BR0116482A BR0116482-1A BR0116482A BR0116482A BR 0116482 A BR0116482 A BR 0116482A BR 0116482 A BR0116482 A BR 0116482A BR 0116482 A BR0116482 A BR 0116482A
Authority
BR
Brazil
Prior art keywords
compounds
preparation
medicaments containing
derivatives
diphenylazetidinone derivatives
Prior art date
Application number
BR0116482-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Heiner Glombik
Werner Kramer
Stefanie Flohr
Wendelin Frick
Hubert Heuer
Gerhard Jaehne
Andreas Lindenschmidt
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Deutschaland Gm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10064402A external-priority patent/DE10064402A1/de
Priority claimed from DE2001154520 external-priority patent/DE10154520A1/de
Application filed by Aventis Pharma Deutschaland Gm filed Critical Aventis Pharma Deutschaland Gm
Publication of BR0116482A publication Critical patent/BR0116482A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0116482-1A 2000-12-21 2001-12-11 Derivados de difenilazetidinona, processo para a preparação, medicamentos contendo esses compostos e seu emprego. BR0116482A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10064402A DE10064402A1 (de) 2000-12-21 2000-12-21 Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE2001154520 DE10154520A1 (de) 2001-11-07 2001-11-07 Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP2001/014532 WO2002050068A1 (de) 2000-12-21 2001-12-11 Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (1)

Publication Number Publication Date
BR0116482A true BR0116482A (pt) 2004-02-03

Family

ID=26008045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116482-1A BR0116482A (pt) 2000-12-21 2001-12-11 Derivados de difenilazetidinona, processo para a preparação, medicamentos contendo esses compostos e seu emprego.

Country Status (23)

Country Link
US (1) US6498156B2 (enExample)
EP (1) EP1345932B1 (enExample)
JP (1) JP2004516293A (enExample)
KR (1) KR20030061462A (enExample)
CN (1) CN1222522C (enExample)
AR (1) AR034282A1 (enExample)
AT (1) ATE342899T1 (enExample)
AU (2) AU2002219173B2 (enExample)
BR (1) BR0116482A (enExample)
CA (1) CA2431985A1 (enExample)
CZ (1) CZ20031731A3 (enExample)
DE (1) DE50111293D1 (enExample)
EE (1) EE200300237A (enExample)
HR (1) HRP20030499A2 (enExample)
HU (1) HUP0401067A2 (enExample)
IL (1) IL156552A0 (enExample)
MX (1) MXPA03005018A (enExample)
NO (1) NO20032733L (enExample)
NZ (1) NZ526592A (enExample)
PL (1) PL362173A1 (enExample)
SK (1) SK7812003A3 (enExample)
WO (1) WO2002050068A1 (enExample)
YU (1) YU46903A (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
MXPA03005155A (es) * 2000-12-21 2003-09-10 Aventis Pharma Gmbh 1,2-difenilazetidinonas novedosas, procesos para su preparacion, farmacos que contienen compuestos y su uso para el tratamiento del metabolismo afectado de los lipidos.
ATE331512T1 (de) 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
KR20080077033A (ko) * 2001-01-26 2008-08-20 쉐링 코포레이션 혈관 질환을 치료하기 위한 스테롤 흡수 억제제와 심혈관제제의 조합물
IL156488A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
AR034204A1 (es) * 2001-01-26 2004-02-04 Schering Corp Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
AR035739A1 (es) * 2001-01-26 2004-07-07 Schering Corp Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CN1655792A (zh) * 2001-08-22 2005-08-17 安万特医药德国有限公司 1,4－苯并硫杂䓬－1,1－二氧化物衍生物与其它活性成分的组合产物及其用途
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227507A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
CN1678296A (zh) * 2002-07-30 2005-10-05 卡里凯昂公司 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法
JP2006508189A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 自己免疫障害の処置のためのコレステロール吸収インヒビター
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
JP5172146B2 (ja) * 2003-05-09 2013-03-27 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 癌を標的化するための組成物及び方法
EP1660456A2 (en) * 2003-08-25 2006-05-31 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
WO2005067903A1 (en) * 2004-01-20 2005-07-28 Panacea Biotec Ltd. Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
HRP20130115T4 (hr) 2004-03-05 2016-04-22 The Trustees Of The University Of Pennsylvania Postupci liječenja poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
CA2580690A1 (en) * 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
JP2008543744A (ja) * 2005-05-09 2008-12-04 マイクロビア インコーポレーテッド 有機金属ベンゼンホスホナートカップリング剤
WO2006122216A2 (en) * 2005-05-11 2006-11-16 Microbia, Inc. Processes for production of phenolic 4-biphenylylazetidin-2-ones
EA200702614A1 (ru) * 2005-05-25 2008-04-28 Майкробиа, Инк. Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот
DE602006010870D1 (de) * 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1951224A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
RU2008133381A (ru) * 2006-01-18 2010-02-27 Шеринг Корпорейшн (US) Модуляторы каннабиноидного рецептора
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008039829A2 (en) * 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
BRPI0814806A2 (pt) * 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102746249B (zh) * 2012-07-07 2013-12-25 山东诚创医药技术开发有限公司 一种依折麦布中间体的纯化精制方法
JP2023536855A (ja) 2020-07-29 2023-08-30 アムリット・ファーマシューティカルズ・インコーポレイテッド 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2191455A1 (en) * 1994-06-20 1995-12-28 Wayne Vaccaro Substituted azetidinone compounds useful as hypocholesterolemic agents
DE69520364T2 (de) * 1994-09-13 2001-09-13 Monsanto Company, St. Louis Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate-aufnahme
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
NO20032733L (no) 2003-08-14
DE50111293D1 (de) 2006-11-30
AU2002219173B2 (en) 2006-06-22
PL362173A1 (en) 2004-10-18
HUP0401067A2 (hu) 2004-09-28
NO20032733D0 (no) 2003-06-16
MXPA03005018A (es) 2003-09-25
IL156552A0 (en) 2004-01-04
AR034282A1 (es) 2004-02-18
US20020128252A1 (en) 2002-09-12
SK7812003A3 (en) 2004-01-08
WO2002050068A1 (de) 2002-06-27
EP1345932A1 (de) 2003-09-24
AU1917302A (en) 2002-07-01
US6498156B2 (en) 2002-12-24
JP2004516293A (ja) 2004-06-03
NZ526592A (en) 2004-11-26
CA2431985A1 (en) 2002-06-27
CN1222522C (zh) 2005-10-12
ATE342899T1 (de) 2006-11-15
KR20030061462A (ko) 2003-07-18
CN1481381A (zh) 2004-03-10
HK1059936A1 (en) 2004-07-23
CZ20031731A3 (cs) 2003-09-17
EE200300237A (et) 2003-08-15
HRP20030499A2 (en) 2005-04-30
EP1345932B1 (de) 2006-10-18
YU46903A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
BR0116482A (pt) Derivados de difenilazetidinona, processo para a preparação, medicamentos contendo esses compostos e seu emprego.
BR0116322A (pt) Derivados de difenilazetidinona, processo para sua preparação, medicamentos contendo esses compostos e seu emprego
BR9911123A (pt) Derivados de dióxido de benzotiepina-1,1, processo para sua preparação, medicamentos contendo esses compostos e seu emprego
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BR0116325A (pt) 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR0311896A (pt) Difenilazetidinonas substituìdas com grupos ácidos, processo para sua preparação, medicamentos contendo estes compostos e seu uso
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR9808540A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica e processo para preparação dos mesmos, uso de um composto, e, processo para produzir a imunossupressão
BR9912240A (pt) Benzocicloheptenos, processo para a sua preparação, preparados farmacêuticos, que contêm os mesmos bem como seu emprego para a preparação de medicamentos
BR0213350A (pt) Derivados benzoxazina e benzotiazina e composições farmacêuticas contendo os mesmos
BR9811022A (pt) Composto, composição farmacêutica, e, processo para preparação de um composto
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0211289A (pt) Derivados de dolastatina 10
BR0116571A (pt) Compostos heterocìclicos tendo atividade antibacteriana, processo para sua preparação e composições farmacêuticas contendo os mesmos
BRPI0408920A (pt) difenilazetidinona com propriedades fisiológicas aperfeiçoadas, processo para a sua preparação, medicamentos contendo esses compostos e sua aplicação
BR0212069A (pt) Agentes antidiabéticos orais
BR0311984A (pt) Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR0108605A (pt) Derivados de 8,8a-dihidro-indeno[1,2-d]tiazol, que na posição 8a são substituìdos; processos para a sua preparação e seu emprego como medicamentos, por exemplo, como anoréxicos
BR9914266A (pt) Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
BR9907934A (pt) Composto, composição farmacêutica, e, processo para a preparação do composto
BR0311646A (pt) Derivados de ácido n-benzoilureido cinâmico, processo para sua preparação e seu emprego

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A, E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.